Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
10
11
12
13
14
15
16
19
11:00 AM - Charmalot 2025
20
21
22
23
24
25
26
27
29
1
2
3
4
5
Oracle Health and Life Sciences Summit 2025
2025-09-09 - 2025-09-11    
12:00 am
The largest gathering of Oracle Health (Formerly Cerner) users. It seems like Oracle Health has learned that it’s not enough for healthcare users to be [...]
MEDITECH Live 2025
2025-09-17 - 2025-09-19    
8:00 am - 4:30 pm
This is the MEDITECH user conference hosted at the amazing MEDITECH conference venue in Foxborough (just outside Boston). We’ll be covering all of the latest [...]
AI Leadership Strategy Summit
2025-09-18 - 2025-09-19    
12:00 am
AI is reshaping healthcare, but for executive leaders, adoption is only part of the equation. Success also requires making informed investments, establishing strong governance, and [...]
OMD Educates: Digital Health Conference 2025
2025-09-18 - 2025-09-19    
7:00 am - 5:00 pm
Why Attend? This is a one-of-a-kind opportunity to get tips from experts and colleagues on how to use your EMR and other innovative health technology [...]
Charmalot 2025
2025-09-19 - 2025-09-21    
11:00 am - 9:00 pm
This is the CharmHealth annual user conference which also includes the CharmHealth Innovation Challenge. We enjoyed the event last year and we’re excited to be [...]
Civitas 2025 Annual Conference
2025-09-28 - 2025-09-30    
8:00 am
Civitas Networks for Health 2025 Annual Conference: From Data to Doing Civitas’ Annual Conference convenes hundreds of industry leaders, decision-makers, and innovators to explore interoperability, [...]
TigerConnect + eVideon Unite Healthcare Communications
2025-09-30    
10:00 am
TigerConnect’s acquisition of eVideon represents a significant step forward in our mission to unify healthcare communications. By combining smart room technology with advanced clinical collaboration [...]
Pathology Visions 2025
2025-10-05 - 2025-10-07    
8:00 am - 5:00 pm
Elevate Patient Care: Discover the Power of DP & AI Pathology Visions unites 800+ digital pathology experts and peers tackling today's challenges and shaping tomorrow's [...]
Events on 2025-09-09
Events on 2025-09-17
MEDITECH Live 2025
17 Sep 25
MA
Events on 2025-09-18
OMD Educates: Digital Health Conference 2025
18 Sep 25
Toronto Congress Centre
Events on 2025-09-19
Charmalot 2025
19 Sep 25
CA
Events on 2025-09-28
Civitas 2025 Annual Conference
28 Sep 25
California
Events on 2025-10-05

Events

Latest News

New trial finds small benefit of inducing labour over “wait and see” approach for late term pregnancies

pregnancies
Female patient with doctor

But results are not sufficiently conclusive to change current practice, says editorial

Inducing labour at 41 weeks of pregnancy leads to a small reduction in birth complications compared with expectant management (a “wait and see” approach) until 42 weeks in low risk women, finds a clinical trial published by The BMJ today.

However, the absolute risk of serious problems was low in both groups – and a linked editorial says the results are not sufficiently conclusive to change current practice, which is in line with the authors’ interpretation.

Late term pregnancy (at or beyond 42 weeks) affects about 15% of women and is associated with increased problems at birth (known as adverse perinatal outcomes), including death.

Some studies suggest that inducing labour from 41 weeks onwards improves outcomes for both mother and baby, but these studies were different regarding their measures, protocols and time frames of comparison and so the results need to be interpreted with caution.

Yet despite these concerns, induction at 41 weeks is now an accepted policy in many countries throughout the world.

So researchers of the INDEX-team led by senior researcher Esteriek de Miranda at the Amsterdam UMC-University of Amsterdam, set out to compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk pregnancies.

The trial included 1800 women (mainly white and younger than 35 years) with an uncomplicated pregnancy recruited from 123 midwifery practices and 45 hospitals in the Netherlands.

Women were randomised to either induction at 41 weeks or expectant management until 42 weeks with subsequent induction if necessary.

Adverse perinatal outcomes were assessed using a combined measure of the newborn’s health (including perinatal death, Apgar score of less than 7 five minutes after birth, and admission to an intensive care baby unit). Other outcomes included type of delivery and mother’s health just after giving birth.

Fifteen women (1.7%) in the induction group had an adverse perinatal outcome compared with 28 (3.1%) in the expectant management group – an absolute risk difference of 1.4% in favour of the induction group.

Eleven (1.2%) infants in the induction group and 23 (2.6%) in the expectant management group had an Apgar score of less than 7 out of 10 at five minutes.

No infants in the induction group and three (0.3%) in the expectant management group had an Apgar score of less than 4 out of 10 at five minutes.

One fetal death (0.1%) occurred in the induction group and two (0.2%) in the expectant management group. No neonatal deaths (deaths in the first 28 days of life) occurred.

Three (0.3%) infants in the induction group versus 8 (0.9%) in the expectant management group were admitted to an intensive care baby unit.

No significant differences in the mother’s health or in caesarean section rates were found between groups.

The researchers point to some potential limitations, but say in this large trial induction of labour at 41 weeks resulted in less overall adverse perinatal outcome than a policy of expectant management until 42 weeks, although the absolute risk of severe adverse outcome was low in both groups.

As with every intervention in the natural birth process, the decision to induce labour must be made with caution, as the expected benefits should outweigh possible adverse effects for both mother and child, they add.

As such, they say their results “should be used to inform women approaching 41 weeks of pregnancy, so they can weigh the respective outcomes and decide whether to be induced at 41 weeks or to continue pregnancy until 42 weeks.”

In a linked editorial, Professor Sara Kenyon at the University of Birmingham and colleagues welcome this new trial, but say the results “are not sufficiently conclusive to change current practice.”

They point out that, if the Apgar scores are excluded, “the remaining data suggest little to choose between the two management options.” And they warn that increasing induction rates (35% of women giving birth for the first time are currently induced in the UK) “may also impact negatively on women’s birth experience.”

[Ends]

20/02/2019

Notes to Editors
Research: Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
https://www.bmj.com/content/364/bmj.l344

Editorial: Optimising the management of late term pregnancies
https://www.bmj.com/content/364/bmj.l681

Journal: The BMJ